New York, NY / June 10, 2014 / Cardax, Inc. (CDXI) today published a new blog post on The Chairman’s Blog, written by the Company’s Vice President of Research, Dr. Timothy J. King.
HONOLULU, (ISLAND NEWS) -- Groundbreaking longevity results with ZanthoSyn, Cardax’s superior astaxanthin supplement, from the Interventions Testing Program (ITP), funded by the National Institute on ...
HONOLULU, Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that ZanthoSyn ® (60 count), the Company's premium astaxanthin dietary supplement for inflammatory health and ...
Honolulu (KHON2) – There’s another option to ease inflammation, which can contribute to critical health issues ranging from heart disease to cancer. ‘Chronic inflammation plays a major role in most ...
Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that it will be leading a discussion on aging at Chaminade University’s Public Policy Forum series on October 28, 2015. Cardax CEO David G.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results